Sveriges mest populära poddar

Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma

2 min•19 januari 2026

In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights drugmakers raising list prices amid pricing agreements with the Trump administration, and Novartis urges governments to address mounting global trade policy challenges impacting the biopharmaceutical industry.

Fler avsnitt av Pharmaceutical Executive

Pharmaceutical Executive Daily: FDA Approves Datroway

22 maj•2 min

Pharmaceutical Executive Daily: What It Takes to Move Machine Learning

21 maj•3 min

Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio

20 maj•4 min

Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs

19 maj•3 min

Rethinking Pharma's Go-to-Market Formula

19 maj•21 min

Pharmaceutical Executive Daily: FDA Approves Baxdrostat

18 maj•2 min

Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra

15 maj•3 min

Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi

14 maj•4 min

Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu

13 maj•3 min

Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen

11 maj•3 min

Pharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.